Abstract
A lower than normal function of the sympathetic nervous system (SNS) has been identified early in the course of multiple sclerosis (MS) and has been shown to play a role in the pathology of the disease. In addition, the chronic use of many drugs commonly used by MS patients could further downregulate SNS by interfering with norepinephrine (NE) synthesis/release and/or interfering with the function of the adrenergic receptors in both the brain and in the periphery. This drug-induced downregulation of SNS activity, when imposed on a background of SNS dysfunction, could not only promote immune inflammatory and neurodegenerative processes, but also can lead to a reduced clinical response to immunomodulaory therapies. Furthermore, low SNS activity could contribute to a higher prevalence of disorders such as depression, fatigue and osteoporosis, which has been observed in MS patients. An algorithm could be constructed based on the combination of baseline NE plasma levels and SNS response levels to a β-adrenergic agonist stimulus. This algorithm, corrected for age and gender, would have the potential to identify MS patients who have a reduced response to immunomodulatory therapies.
Keywords: Antidepressants, Antihypertensive, Antiplatelets, Autonomic dysfunction, Benzodiazepines, Multiple sclerosis, Noradrenergic receptors, Spasticity, Statins, drug-induced downregulation
Current Pharmaceutical Design
Title:Sympathetic Nervous System Dysfunction in Multiple Sclerosis, Linking Neurodegeneration to a Reduced Response to Therapy
Volume: 18 Issue: 12
Author(s): Zohara Sternberg
Affiliation:
Keywords: Antidepressants, Antihypertensive, Antiplatelets, Autonomic dysfunction, Benzodiazepines, Multiple sclerosis, Noradrenergic receptors, Spasticity, Statins, drug-induced downregulation
Abstract: A lower than normal function of the sympathetic nervous system (SNS) has been identified early in the course of multiple sclerosis (MS) and has been shown to play a role in the pathology of the disease. In addition, the chronic use of many drugs commonly used by MS patients could further downregulate SNS by interfering with norepinephrine (NE) synthesis/release and/or interfering with the function of the adrenergic receptors in both the brain and in the periphery. This drug-induced downregulation of SNS activity, when imposed on a background of SNS dysfunction, could not only promote immune inflammatory and neurodegenerative processes, but also can lead to a reduced clinical response to immunomodulaory therapies. Furthermore, low SNS activity could contribute to a higher prevalence of disorders such as depression, fatigue and osteoporosis, which has been observed in MS patients. An algorithm could be constructed based on the combination of baseline NE plasma levels and SNS response levels to a β-adrenergic agonist stimulus. This algorithm, corrected for age and gender, would have the potential to identify MS patients who have a reduced response to immunomodulatory therapies.
Export Options
About this article
Cite this article as:
Zohara Sternberg , Sympathetic Nervous System Dysfunction in Multiple Sclerosis, Linking Neurodegeneration to a Reduced Response to Therapy , Current Pharmaceutical Design 2012; 18 (12) . https://dx.doi.org/10.2174/138161212799958639
DOI https://dx.doi.org/10.2174/138161212799958639 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of Dietary Supplementation of Black Seed (N. Sativa L.) on Lipid Profile of Patients Suffering from Diabetes
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry synthesis and Structure-Activity Relationships of 2,3-Benzodiazepines as AMPA Receptor Antagonists
Mini-Reviews in Medicinal Chemistry New Insights into the Roles of Endolysosomal Cathepsins in the Pathogenesis of Alzheimers Disease: Cathepsin Inhibitors as Potential Therapeutics
CNS & Neurological Disorders - Drug Targets GABA System as a Target for New Drugs
Current Medicinal Chemistry Psychobiological Model of Personality: Guidelines for Pharmacotherapy of Personality Disorder
Current Psychopharmacology Management of Antiepileptic Treatment After Epilepsy Surgery - Practices and Problems
Current Pharmaceutical Design ENaC in the Brain - Future Perspectives and Pharmacological Implications
Current Molecular Pharmacology Delirium Secondary to Lamotrigine Toxicity
Current Drug Safety Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Neuropathic Pain and Lung Delivery of Nanoparticulate Drugs: An Emerging Novel Therapeutic Strategy
CNS & Neurological Disorders - Drug Targets Extraction, GC-MS Evaluation and Anti-epileptic Potential of Seeds Ethanolic Extract of Putranjiva roxburghii Wall
Central Nervous System Agents in Medicinal Chemistry Association Between Seizures and Diabetes Mellitus: A Comprehensive Review of Literature
Current Diabetes Reviews Retigabine: Could it be the Next Broad-Spectrum Antiepileptic Drug?
Current Drug Therapy Borna Disease Virus (BDV): Neuropharmacological Effects of a CNS Viral Infection
Current Neuropharmacology p75NTR as a Therapeutic Target for Neuropsychiatric Diseases
Current Molecular Pharmacology Use of Antiepileptic Drugs for Hyperkinetic Movement Disorders
Current Neuropharmacology Transglutaminase Activity as a Possible Therapeutical Target in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Brain Adaptation to Stressful Stimuli: A New Perspective on Potential Therapeutic Approaches Based on BDNF and NMDA Receptors
CNS & Neurological Disorders - Drug Targets Design, Synthesis of 6-Substituted-pyrido[3,2-d]pyridazine Derivatives with Anticonvulsant Activity
Medicinal Chemistry Dietary Flavonoids Interaction with CREB-BDNF Pathway: An Unconventional Approach for Comprehensive Management of Epilepsy
Current Neuropharmacology